1.3800
-0.1100
(-7.38%)
At close: April 3 at 4:00:02 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Expense
73,267
73,267
54,796
46,469
25,301
Operating Income
-73,267
-73,267
-54,796
-46,469
-25,301
Net Non Operating Interest Income Expense
7,892
7,892
5,282
668
96
Other Income Expense
12
12
80
-100
-5
Pretax Income
-65,363
-65,363
-49,434
-45,901
-25,210
Net Income Common Stockholders
-65,363
-65,363
-49,434
-45,901
-25,210
Diluted NI Available to Com Stockholders
-65,363
-65,363
-49,434
-45,901
-25,210
Basic EPS
-3.85
--
-2.22
-3.28
-1.80
Diluted EPS
-3.85
--
-2.22
-3.28
-1.80
Basic Average Shares
16,984
--
22,239.3330
13,990
13,990
Diluted Average Shares
16,984
--
22,239.3330
13,990
13,990
Total Operating Income as Reported
-73,267
-73,267
-54,796
-46,469
-25,301
Total Expenses
73,267
73,267
54,796
46,469
25,301
Net Income from Continuing & Discontinued Operation
-65,363
-65,363
-49,434
-45,901
-25,210
Normalized Income
-65,363
-65,363
-49,434
-45,901
-25,210
Interest Income
7,892
7,892
5,282
668
96
Net Interest Income
7,892
7,892
5,282
668
96
EBIT
-73,267
-73,267
-54,796
-46,469
-25,301
EBITDA
-72,181
-72,181
-53,839
-45,527
-24,619
Reconciled Depreciation
1,086
1,086
957
942
682
Net Income from Continuing Operation Net Minority Interest
-65,363
-65,363
-49,434
-45,901
-25,210
Normalized EBITDA
-72,181
-72,181
-53,839
-45,527
-24,619
12/31/2021 - 3/28/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CTNM Contineum Therapeutics, Inc.
6.13
-9.59%
KYTX Kyverna Therapeutics, Inc.
1.9700
-8.37%
PMVP PMV Pharmaceuticals, Inc.
0.9950
-0.50%
MAZE Maze Therapeutics, Inc.
9.32
-10.13%
ARTV Artiva Biotherapeutics, Inc.
2.5400
-11.19%
RAPP Rapport Therapeutics, Inc.
8.52
-14.46%
SEPN Septerna, Inc.
5.80
+5.55%
MBX MBX Biosciences, Inc.
6.37
-8.61%
SEER Seer, Inc.
1.6600
-1.78%
ZURA Zura Bio Limited
1.0850
-7.26%